Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Xylazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.94 |
| ▸ | TSHR | P16473 | 1/20 | 0.94 |
| ▸ | RAB9A | P51151 | 1/20 | 0.94 |
| ▸ | MAPT | P10636 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylazine SCHEMBL15487 | 0.97 | LMNA (1.00) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL1228390 | 0.95 | LMNA (1.00) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL38986 | 0.95 | LMNA (1.00) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL1119093 | 0.95 | LMNA (1.00) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL18988891 | 0.95 | LMNA (0.97) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL22616146 | 0.95 | LMNA (0.97) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL9808825 | 0.88 | LMNA (0.83) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL22616197 | 0.88 | LMNA (0.83) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL22616203 | 0.88 | RAB9A (0.83) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL28343930 | 0.88 | LMNA (0.83) | LMNACYP3A4CYP2D6TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4417219-A1 | MAGNETIC BIOMOLECULE-METAL ION SELF-ASSEMBLED COMPLEX FOR TREATMENT | Korea University Research and Business Foundation (KR) | 2024-08-21 | — | — | EP | disclosed |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| US-20220381657-A1 | METHOD FOR PREPARING BIOLOGICAL MATERIAL HAVING EXCELLENT LIGHT-TRANSMITTING PROPERTY | RIKEN (JP) | 2022-12-01 | — | — | US | disclosed |
| CN-114441663-A | Method for screening protein positive compounds by using solid phase microextraction affinity selection mass spectrum | 中国科学院上海药物研究所 | 2022-05-06 | — | — | CN | disclosed |
| US-8242152-B2 | Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for the prophylaxis and treatment of osteoporosis | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2012-08-14 | — | — | US | disclosed |
| US-20100160394-A1 | USE OF 4-[(4- THIAZOLYL)PHENOXY]ALKOXY-BENZAMIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF OSTEOPOROSIS | DONGWHA PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160394-A1 | USE OF 4-[(4- THIAZOLYL)PHENOXY]ALKOXY-BENZAMIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF OSTEOPOROSIS | SOST, PTH1R, PTMS | LMNA 1454/4885CYP3A4 361/4885CYP2D6 881/4885 |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | SYNCRIP, FUS, SARS1 | LMNA 1111/4885CYP3A4 1214/4885CYP2D6 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.